Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) Enterprise Value: 2011-2025

Historic Enterprise Value for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $231.1 million.

  • Capricor Therapeutics' Enterprise Value fell 43.63% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$188.0 million, marking a year-over-year decrease of 162.47%. This contributed to the annual value of $476.0 million for FY2024, which is 328.46% up from last year.
  • Capricor Therapeutics' Enterprise Value amounted to $231.1 million in Q3 2025, which was down 30.21% from $331.1 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Enterprise Value high stood at $476.0 million for Q4 2024, and its period low was $25.0 million during Q1 2022.
  • Over the past 3 years, Capricor Therapeutics' median Enterprise Value value was $173.3 million (recorded in 2024), while the average stood at $213.4 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Enterprise Value soared by 2,663.80% in 2021, and later crashed by 61.40% in 2022.
  • Over the past 5 years, Capricor Therapeutics' Enterprise Value (Quarterly) stood at $35.9 million in 2021, then skyrocketed by 56.14% to $56.0 million in 2022, then surged by 98.34% to $111.1 million in 2023, then spiked by 328.46% to $476.0 million in 2024, then crashed by 43.63% to $231.1 million in 2025.
  • Its Enterprise Value stands at $231.1 million for Q3 2025, versus $331.1 million for Q2 2025 and $288.7 million for Q1 2025.